D-2570 Tablet: D-2570 is a novel inhibitor targeting the TYK2 pseudokinase domain
BMS-986165 Tablet: BMS-986165 is a novel inhibitor targeting TYK2
Placebo: A placebo refers to a tablet that has no therapeutic effect on medication
Study summary
This study is a randomized, double-blind, placebo- and active-controlled multicenter clinical trial involving patients with moderate to severe plaque psoriasis.
Safety and efficacy assessments will be conducted during the scheduled study visits throughout the trial. After completing the respective treatment, all subjects will undergo a safety follow-up. Both the investigators and subjects will remain blinded throughout the entire treatment period.
During the study, subjects are required to provide blood samples for pharmacokinetic (PK) and pharmacodynamic (PD) analyses at the time points specified in the trial protocol.
Eligibility
Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria:
* The patient voluntarily participates in this study after providing fully informed consent, signs a written informed consent form, and agrees to comply with the procedures specified in the study protocol;
* Aged between 18 and 70 years old (inclusive) at the time of signing the informed consent form, regardless of gender;
* The investigator assesses that the subject has plaque psoriasis suitable for systemic therapy, and the condition has been stable for ≥ 6 months before signing the informed consent form;
* At the screening stage and Day 1 (D1) of the treatment period, the Psoriasis Body Surface Area (BSA) is ≥10%, the Physician Global Assessment (PGA) score is ≥ 3 points, and the Psoriasis Area and Severity Index (PASI) score is ≥ 12 points;
* Hematology, Blood chemistry and Urinalysis examination were basically normal;
* Male subjects and female subjects of childbearing potential must agree to abstain from sexual intercourse or adopt effective contraceptive measures from the time of signing the informed consent form (ICF) until 30 days after the last administration of the investigational product.
Exclusion Criteria:
* Suffering from any type of psoriasis including erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, inverse psoriasis, or drug-induced psoriasis;
* Having other skin lesions that may interfere with the assessment of treatment outcomes, such as eczema;
* A history of severe herpes zoster/simplex infection;
* A history of tuberculosis, active tuberculosis, latent tuberculosis, or clinical manifestations suggestive of tuberculosis infection
* Having language barriers, or being unwilling or unable to fully understand and cooperate;
* Being pregnant or lactating women;
* Other circumstances that the investigator deems unsuitable for the subject to participate in the study.
Primary outcome measure(s)
To evaluate the efficacy of different doses of D-2570 compared with placebo in the treatment of patients with moderate to severe plaque psoriasis — Treatment for 16 weeks after enrollment Psoriasis Area and Severity Index (PASI)
To evaluate the efficacy of different doses of D-2570 compared with placebo in the treatment of patients with moderate to severe plaque psoriasis — Treatment for 16 weeks after enrollment Physician Global Assessment (PGA)
To evaluate the efficacy of different doses of D-2570 compared with placebo in the treatment of patients with moderate to severe plaque psoriasis — Treatment for 16 weeks after enrollment Dermatology Life Quality Index (DLQI)
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.